T-knife Therapeutics Presents Preclinical Data at the American Association for Cancer Research ...

T-knife Therapeutics Presents Preclinical Data at the American Association for Cancer Research ...

– TK-6302, a supercharged PRAME targeting TCR-T therapy, demonstrates best-in-class preclinical anti-tumor efficacy as compared to current clinical stage PRAME TCR-T approaches, providing the potential for broad, deep and durable responses in hard-to-treat solid tumor indications

Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025 - Elevation Oncology

— EO-1022 is a potentially differentiated HER3 ADC designed to address significant unmet needs across multiple solid tumors — — On-track to file IND application in 2026 — BOSTON, April 25, 2025 /PRNewswire/ — Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today anno…